FILTER
FILTERED INTERVIEW RESULTS
Manni Kantipudi & Ramesh Subramanian
CEO & CCO, ARAGEN LIFE SCIENCES
Aragen Life Sciences continues its rapid expansion and celebrates its best year ever.
Jose Antonio Moreno Toscano
CEO, LFB USA
LFB speaks to GBR as it begins the commercialization of Sevenfact and ATryn.
Salvatore Butti
PRESIDENT, ASSOSALUTE - FEDERCHIMICA
Assosalute represents non-prescription medical products in Italy and explains how easing regulations could be of huge benefit to Italians and the healthcare system.
Dr. Siva Samy
CEO & CHIEF PRODUCT STRATEGIST, VALGENESIS
ValGenesis explains how it streamlines the validation process to allow real-time access to validation documents and data enabling various stakeholders to achieve compliance efficiently.
Michael Kauffman
CEO, KARYOPHARM THERAPEUTICS
GBR speaks to Karyopharm Therapeutics about the commercialization of XPOVIO.
Paolo Russolo
PRESIDENT, ASCHIMFARMA – FEDERCHIMICA
Aschimfarma explains to GBR how Italian producers of APIs are well positioned to strengthen the European drug supply chain.
Eric Ostertag M.D., Ph.D.
CEO, POSEIDA THERAPEUTICS
Poseida Therapeutics explains how progress in gene therapy offers the possibility to provide single treatment cures for cancer and other genetic diseases.
Amit Munshi
PRESIDENT & CEO, ARENA PHARMACEUTICALS
Arena Pharmaceuticals speaks to GBR about building its pipeline and infrastructure.
Dr. Andrea Pfeifer
CO-FOUNDER & CEO, AC IMMUNE
AC Immune describes its research into neurodegenerative diseases.
Mark Egerton
CEO, QUOTIENT SCIENCES
Quotient Sciences is a drug development and manufacturing accelerator that supports pharmaceutical and biotech companies with services spanning the entire development pathway from candidate selection to commercial launch.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
